Evidence map›Paper›PMID 28417559›Full record

ArticleCNS neuroscience & therapeutics2017

Asenapine modulates mood-related behaviors and 5-HT

Sarah Delcourte, Erika Abrial, Adeline Etiévant, Renaud Rovera, Jørn Arnt, Michael Didriksen, Nasser Haddjeri

Open access · bronzeAbstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Asenapine modulates mood-related behaviors and 5-HTCNS neuroscience & therapeutics · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Sarah DelcourteInserm, Stem Cell and Brain Research Institute U1208, Univ Lyon, Université Lyon 1, Bron, France.
Erika AbrialInserm, Stem Cell and Brain Research Institute U1208, Univ Lyon, Université Lyon 1, Bron, France.
Adeline EtiévantIntegrative and Clinical Neurosciences EA481, University of Bourgogne Franche-Comté, Besançon, France.
Renaud RoveraInserm, Stem Cell and Brain Research Institute U1208, Univ Lyon, Université Lyon 1, Bron, France.
Jørn ArntSunred Pharma Consulting Aps, Solrød Strand, Denmark.
Michael DidriksenDepartment of Synaptic Transmission 2, H Lundbeck A/S, Valby, Denmark.
Nasser HaddjeriInserm, Stem Cell and Brain Research Institute U1208, Univ Lyon, Université Lyon 1, Bron, France.ORCID http://orcid.org/0000-0002-2161-2204
Université Claude Bernard Lyon 1 · FRLundbeck (Denmark) · DKUniversité Bourgogne Franche-Comté · FRZealand Pharma (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAsenapine is a new atypical antipsychotic prescribed for the treatment of psychosis/bipolar disorders that presents higher affinity for serotonergic than dopaminergic receptors. The objective of this study was to investigate its antidepressant-like and antimanic-like properties on relevant animal models of depression and mania and to assess the acute and chronic effect of Asenapine on dorsal raphe nucleus (DRN) 5-HT cell firing activity.

methodsWe assessed the effects of Asenapine using in vivo electrophysiological and behavioral assays in rats.

resultsBehavioral experiments showed that Asenapine had no significant effect on immobility time in the forced swim test (FST) in control rats. In the ACTH-treated rats, a model of antidepressant-resistance, Asenapine failed to alter immobility time in the FST. In contrast in the sleep deprivation (SD) model of mania, acute administration of Asenapine significantly decreased the hyperlocomotion of SD rats. In the DRN, acute administration of Asenapine reduced the suppressant effect of the selective 5-HT

conclusionThese results confirm that Asenapine displays robust antimanic property and effective in vivo antagonistic activity at 5-HT

Indexed as

Adrenergic alpha-2 Receptor AgonistsAdrenocorticotropic HormoneAffectAnimalsAntipsychotic AgentsDexmedetomidineDibenzocycloheptenesDisease Models, AnimalDrug Delivery SystemsHeterocyclic Compounds, 4 or More RingsMaleNeuronsRatsRats, Sprague-DawleyReceptor, Serotonin, 5-HT1AReceptors, SerotoninAdrenergic alpha-2 Receptor AgonistsAdrenocorticotropic HormoneAntipsychotic AgentsasenapineDexmedetomidineDibenzocycloheptenesHeterocyclic Compounds, 4 or More RingsReceptor, Serotonin, 5-HT1AReceptors, Serotoninserotonin 7 receptorSerotonin Agents5-HT1A/7Asenapineelectrophysiologymanic-like and depressive-like behaviorsraphe

Identifiers

PMID28417559
PMCPMC6492759
OpenAlexW2606776923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.